Lung Fibrosis
12
5
6
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (12)
Home-based Pulmonary Rehabilitation and Health Coaching in Patients With Fibrotic Interstitial Lung Disease
Impact of Airway Mucus Plugs on Secondary Pulmonary Fibrosis in COPD Patients: A Single-Center Case-Control Study
Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease
Pulmonary Outcomes on Patients With Lung Fibrosis
Pulmonary Fibrosis Foundation Community Registry
Immune Modulation by Exosomes in COVID-19
Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
Digital App for Telerehabilitation in Respiratory Diseases
Anti-Inflammatory and Anti-Fibrotic Drugs in Post COVID-19 Pulmonary Fibrosis
Study to Assess Efficacy and Safety of Treamid for Patients With Reduced Exercise Tolerance After COVID-19
Low-field Magnetic Resonance Imaging of Pediatric COVID-19
A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis